SCOPUS 정보 검색 플랫폼

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1622-1626

Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan

(1) Moritoyo, Takashi a,b

a UNIVERSITY OF TOKYO HOSPITAL (Japan)

b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (Japan)

Author keywords

biomarker; clinical evaluation; Key words Alzheimer's disease; regulatory science

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; NEW DRUG; TAU PROTEIN; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL EVALUATION; CLINICAL STUDY; DRUG DEVELOPMENT; DRUG RESEARCH; HUMAN; JAPAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; LEGISLATION AND JURISPRUDENCE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; JAPAN; NOOTROPIC AGENTS;

EID: 84940513745 PISSN: 01492918 EISSN: 1879114X Source Type: Journal
DOI: 10.1016/j.clinthera.2015.04.014 Document Type: Article

Times cited : (5)

References (8)

1
- 84893454720
- New and future treatments for neurological disorders - Knowledge essential to daily clinics and future prospects. Topics: 2. Dementia [in Japanese]
- T. Moritoyo New and future treatments for neurological disorders - knowledge essential to daily clinics and future prospects. Topics: 2. Dementia [in Japanese] Nihon Naika Gakkai Zasshi 102 2013 1916 1922
- (2013) Nihon Naika Gakkai Zasshi , vol.102 , pp. 1916-1922
- Moritoyo, T.¹

2
- 77953518555
- Alzheimer's disease: Clinical trials and drug development
- F. Mangialasche, A. Solomon, B. Winblad, and et al. Alzheimer's disease: clinical trials and drug development Lancet Neurol 9 2010 702 716
- (2010) Lancet Neurol , vol.9 , pp. 702-716
- Mangialasche, F.¹ Solomon, A.² Winblad, B.³

3
- 84940507325
- Last accessed April 22, 2015.
- http://www.pmda.go.jp/rs-std-jp/facilitate-developments/0026.html. Last accessed April 22, 2015.

4
- 84883552519
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
- M.W. Weiner, D.P. Veitch, P.S. Aisen, and et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
- (2013) Alzheimers Dement , vol.9 , pp. e111-e194
- Weiner, M.W.¹ Veitch, D.P.² Aisen, P.S.³

5
- 84940540404
- Guidance for industry: Alzheimer's Disease: Developing drugs for the treatment of early state disease. Last accessed April 22
- U.S. Department of Health and Human Service. Guidance for industry: Alzheimer's Disease: Developing drugs for the treatment of early state disease. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf. Last accessed April 22, 2015
- (2015)

6
- 84973383759
- FDA's draft guidance targets drug development for early stages of Alzheimer's disease
- C. Stong FDA's draft guidance targets drug development for early stages of Alzheimer's disease Neurology Reviews 21 2013 80
- (2013) Neurology Reviews , vol.21 , pp. 80
- Stong, C.¹

7
- 84875514732
- Regulatory innovation and drug development for early-stage Alzheimer's disease
- N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
- (2013) N Engl J Med , vol.368 , pp. 1169-1171
- Kozauer, N.¹ Katz, R.²

8
- 84940547840
- Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. Last accessed April 22
- European Medicines Agency. Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176827.pdf. Last accessed April 22
- (2015)
- European Medicines Agency¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.